Study shows hydroxyurea to be safe for children with sickle cell anemia
Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa. Hydroxyurea use reduced the incidence of vaso-occlusive events, infections, malaria, transfusions, and death, which supports the need for wider access to treatment. These findings were published December 1, 2018 in the New England Journal of Medicine.
To continue reading this article
Continue reading your article with a eMediNexus account.